Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 04, 2021, titled "Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg:Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg".